Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3.

Kleinman ME, Kaneko H, Cho WG, Dridi S, Fowler BJ, Blandford AD, Albuquerque RJ, Hirano Y, Terasaki H, Kondo M, Fujita T, Ambati BK, Tarallo V, Gelfand BD, Bogdanovich S, Baffi JZ, Ambati J.

Mol Ther. 2012 Jan;20(1):101-8. doi: 10.1038/mt.2011.212. Epub 2011 Oct 11.

2.

Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.

Polach KJ, Matar M, Rice J, Slobodkin G, Sparks J, Congo R, Rea-Ramsey A, McClure D, Brunhoeber E, Krampert M, Schuster A, Jahn-Hofmann K, John M, Vornlocher HP, Fewell JG, Anwer K, Geick A.

Mol Ther. 2012 Jan;20(1):91-100. doi: 10.1038/mt.2011.210. Epub 2011 Oct 11.

3.

Therapeutic siRNA silencing in inflammatory monocytes in mice.

Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y, Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R, Anderson DG, Nahrendorf M.

Nat Biotechnol. 2011 Oct 9;29(11):1005-10. doi: 10.1038/nbt.1989.

4.

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR.

Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.

5.

Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD, Swiderski P, Aboellail T, Huang Y, Du Q, Liang Z, Peng L, Akkina R, Rossi JJ.

Mol Ther. 2011 Dec;19(12):2228-38. doi: 10.1038/mt.2011.207. Epub 2011 Sep 27.

6.

Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein.

Kuwahara H, Nishina K, Yoshida K, Nishina T, Yamamoto M, Saito Y, Piao W, Yoshida M, Mizusawa H, Yokota T.

Mol Ther. 2011 Dec;19(12):2213-21. doi: 10.1038/mt.2011.186. Epub 2011 Sep 13.

7.

Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery.

Shi B, Keough E, Matter A, Leander K, Young S, Carlini E, Sachs AB, Tao W, Abrams M, Howell B, Sepp-Lorenzino L.

J Histochem Cytochem. 2011 Aug;59(8):727-40. doi: 10.1369/0022155411410885.

8.

Structural diversity repertoire of gene silencing small interfering RNAs.

Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK.

Nucleic Acid Ther. 2011 Jun;21(3):125-31. doi: 10.1089/nat.2011.0286. Review.

9.

Current progress of siRNA/shRNA therapeutics in clinical trials.

Burnett JC, Rossi JJ, Tiemann K.

Biotechnol J. 2011 Sep;6(9):1130-46. doi: 10.1002/biot.201100054. Epub 2011 Jul 11. Review.

10.

siRNA repositioning for guide strand selection by human Dicer complexes.

Noland CL, Ma E, Doudna JA.

Mol Cell. 2011 Jul 8;43(1):110-21. doi: 10.1016/j.molcel.2011.05.028.

11.

Interaction of poly(ethylenimine)-DNA polyplexes with mitochondria: implications for a mechanism of cytotoxicity.

Grandinetti G, Ingle NP, Reineke TM.

Mol Pharm. 2011 Oct 3;8(5):1709-19. doi: 10.1021/mp200078n. Epub 2011 Jul 18.

12.

Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing.

Al-Jamal KT, Gherardini L, Bardi G, Nunes A, Guo C, Bussy C, Herrero MA, Bianco A, Prato M, Kostarelos K, Pizzorusso T.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10952-7. doi: 10.1073/pnas.1100930108. Epub 2011 Jun 20.

13.
14.

Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer.

Suo WH, Zhang N, Wu PP, Zhao L, Song LJ, Shen WW, Zheng L, Tao J, Long XD, Fu GH.

Br J Pharmacol. 2012 Jan;165(1):135-47. doi: 10.1111/j.1476-5381.2011.01521.x.

15.

Inhibition of aldose reductase prevents colon cancer metastasis.

Tammali R, Reddy AB, Saxena A, Rychahou PG, Evers BM, Qiu S, Awasthi S, Ramana KV, Srivastava SK.

Carcinogenesis. 2011 Aug;32(8):1259-67. doi: 10.1093/carcin/bgr102. Epub 2011 Jun 3.

16.

STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi AO, Uludağ H, Lavasanifar A.

Transl Oncol. 2011 Jun;4(3):178-88. Epub 2011 Jun 1.

17.

Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.

Xiong XB, Lavasanifar A.

ACS Nano. 2011 Jun 28;5(6):5202-13. doi: 10.1021/nn2013707. Epub 2011 Jun 10.

PMID:
21627074
18.

The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing.

Herbert M, Coppieters N, Lasham A, Cao H, Reid G.

BMC Res Notes. 2011 May 25;4:148. doi: 10.1186/1756-0500-4-148.

19.

Silencing of sodium/hydrogen exchanger in the heart by direct injection of naked siRNA.

Morgan PE, Correa MV, Ennis IL, Diez AA, Pérez NG, Cingolani HE.

J Appl Physiol (1985). 2011 Aug;111(2):566-72. doi: 10.1152/japplphysiol.00200.2011. Epub 2011 May 19. Erratum in: J Appl Physiol. 2012 Mar;112(6):1091. Ennis, Irene E [corrected to Ennis, Irene L].

20.

A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.

Chen H, Chen L, Sun L, Zhen H, Li X, Zhang Q.

Gastric Cancer. 2011 Oct;14(4):339-52. doi: 10.1007/s10120-011-0049-x. Epub 2011 May 3.

PMID:
21538018

Supplemental Content

Support Center